Thursday, June 7, 2012
Bristol-Myers Squibb Co., of New York, said the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis Subjects With Background Methotrexate) study met its primary endpoint, as measured by noninferiority, and demonstrated that Orencia (abatacept) plus methotrexate achieved comparable rates of efficacy to Humiara (adalimumab, Abbott) for the American College of Rheumatology criteria of 20 percent response at one year (63.4 percent vs. 64.8 percent).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.